NO20010651L - Inhibering av type 3 3<alfa>-hydroxysteroiddehydrogenase - Google Patents
Inhibering av type 3 3<alfa>-hydroxysteroiddehydrogenaseInfo
- Publication number
- NO20010651L NO20010651L NO20010651A NO20010651A NO20010651L NO 20010651 L NO20010651 L NO 20010651L NO 20010651 A NO20010651 A NO 20010651A NO 20010651 A NO20010651 A NO 20010651A NO 20010651 L NO20010651 L NO 20010651L
- Authority
- NO
- Norway
- Prior art keywords
- type
- hydroxysteroid dehydrogenase
- inhibition
- alpha
- inhibitors
- Prior art date
Links
- 101710088194 Dehydrogenase Proteins 0.000 title abstract 2
- 230000005764 inhibitory process Effects 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 abstract 3
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 abstract 1
- 206010020112 Hirsutism Diseases 0.000 abstract 1
- 102000011145 Hydroxysteroid Dehydrogenases Human genes 0.000 abstract 1
- 108010062875 Hydroxysteroid Dehydrogenases Proteins 0.000 abstract 1
- 206010060862 Prostate cancer Diseases 0.000 abstract 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 abstract 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
- 206010039792 Seborrhoea Diseases 0.000 abstract 1
- 206010000496 acne Diseases 0.000 abstract 1
- 239000008186 active pharmaceutical agent Substances 0.000 abstract 1
- 230000001548 androgenic effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 229940127557 pharmaceutical product Drugs 0.000 abstract 1
- 201000007094 prostatitis Diseases 0.000 abstract 1
- 208000008742 seborrheic dermatitis Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9562398P | 1998-08-07 | 1998-08-07 | |
| PCT/CA1999/000724 WO2000007576A2 (en) | 1998-08-07 | 1999-08-06 | INHIBITORS OF TYPE 3 3α-HYDROSTEROID DEHYDROGENASE |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20010651D0 NO20010651D0 (no) | 2001-02-07 |
| NO20010651L true NO20010651L (no) | 2001-04-05 |
Family
ID=22252842
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20010651A NO20010651L (no) | 1998-08-07 | 2001-02-07 | Inhibering av type 3 3<alfa>-hydroxysteroiddehydrogenase |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP1102582A2 (de) |
| JP (1) | JP2002522380A (de) |
| CN (1) | CN1322130A (de) |
| AR (1) | AR021757A1 (de) |
| AU (1) | AU5144999A (de) |
| CA (1) | CA2339368A1 (de) |
| ID (1) | ID28791A (de) |
| NO (1) | NO20010651L (de) |
| WO (1) | WO2000007576A2 (de) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6908910B2 (en) | 1993-08-06 | 2005-06-21 | The Children's Medical Center Corporation | Estrogenic compounds as anti-mitotic agents |
| US5504074A (en) | 1993-08-06 | 1996-04-02 | Children's Medical Center Corporation | Estrogenic compounds as anti-angiogenic agents |
| EP1321146A3 (de) * | 1998-03-11 | 2004-06-02 | Endorecherche Inc. | Typ 5 und Typ 3 17 Beta-Hydroxisteroid-Dehydrogenasehemmer und Verfahren zu ihrer Anwendung |
| US7087592B1 (en) | 1999-08-23 | 2006-08-08 | Entre Med, Inc. | Compositions comprising purified 2-methoxyestradiol and methods of producing same |
| US6891953B1 (en) | 2000-06-27 | 2005-05-10 | Microsoft Corporation | Method and system for binding enhanced software features to a persona |
| US6995278B2 (en) | 2000-08-18 | 2006-02-07 | Entre Med, Inc. | Antiangiogenic agents |
| US7135581B2 (en) | 2000-08-18 | 2006-11-14 | Entremed, Inc. | Antiangiogenic agents |
| EP1343803A2 (de) * | 2000-11-27 | 2003-09-17 | EntreMed, Inc. | 2-substituierte estrogene mit antiangiogenischer aktivität |
| US6710037B2 (en) * | 2001-05-01 | 2004-03-23 | Schering Corporation | Method of treating androgen-dependent disorders |
| ATE498408T1 (de) * | 2001-08-10 | 2011-03-15 | Takeda Pharmaceutical | Gnrh-agonistische kombinationsmittel |
| CN1679956A (zh) * | 2001-11-29 | 2005-10-12 | Gtx公司 | 治疗因雄激素剥夺引起的症状 |
| US7524866B2 (en) | 2001-11-29 | 2009-04-28 | Gtx, Inc. | Prevention and treatment of androgen—deprivation induced osteoporosis |
| EP1633367A2 (de) | 2003-05-28 | 2006-03-15 | EntreMed, Inc. | Antiangiogene mittel |
| CA2558014A1 (en) | 2004-03-12 | 2005-09-29 | Entremed, Inc. | Antiangiogenic agents |
| DE102004032674A1 (de) * | 2004-07-02 | 2006-01-26 | Schering Ag | Neue 2-substituierte Estra-1,3,5(10)-trien-17-one als Inhibitoren der 17β-Hydroxysteroiddehydrogenase Typ 1 |
| US7419972B2 (en) | 2004-07-02 | 2008-09-02 | Schering Ag | 2-substituted estra-1,3,5(10)-trien-17-ones as inhibitors of 17β-hydroxy steroid dehydrogenase type 1 |
| CA2646065C (en) | 2006-03-20 | 2014-01-14 | Entremed, Inc. | Disease modifying anti-arthritic activity of 2-methoxyestradiol |
| US9284345B2 (en) | 2007-04-12 | 2016-03-15 | Endorecherche, Inc. | 17alpha-substituted steroids as systemic antiandrogens and selective androgen receptor modulators |
| KR20100050444A (ko) * | 2007-08-31 | 2010-05-13 | 아스텔라스세이야쿠 가부시키가이샤 | 피페리딘 유도체 |
| CN101698834B (zh) * | 2009-09-08 | 2012-05-23 | 北京利德曼生化股份有限公司 | 3α-羟基类固醇脱氢酶及其核苷酸序列、重组载体、重组宿主细胞和试剂盒 |
| PE20150353A1 (es) * | 2012-07-10 | 2015-03-28 | Bayer Pharma AG | Derivados de estra-1,3,5(10),16-tetraeno 3-sustituidos, metodos para su preparacion, preparaciones farmaceuticas que los contienen, asi como su uso para la preparacion de medicamentos |
| ES2678993T3 (es) * | 2013-02-21 | 2018-08-21 | Bayer Pharma Aktiengesellschaft | Estra-1,3,5(10),16-tetraeno-3-carboxamidas para la inhibición de la 17beta-hidroxiesteroide deshidrogenada (AKR1C3) |
| CN104873520A (zh) * | 2014-02-27 | 2015-09-02 | 天津药物研究院 | 一种11β-羟基类固醇脱氢酶抑制剂、药用组合物及其用途 |
| CN104873525A (zh) * | 2014-02-27 | 2015-09-02 | 天津药物研究院 | 一种11β-羟基类固醇脱氢酶抑制剂及其药用组合物和用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3562260A (en) * | 1965-08-23 | 1971-02-09 | Ormonoterapia Richter Spa | 2-carbonyl-estratrienes and method of their preparation |
| US4340602A (en) * | 1978-10-18 | 1982-07-20 | Wayne State University | Compositions inhibiting estrogen sulfotransferase activity |
| AU556749B2 (en) * | 1983-02-22 | 1986-11-20 | Liehr, J.G. | Pharmaceutical compositions of 2-fluoroestradiol |
| US4568673A (en) * | 1984-03-20 | 1986-02-04 | Wayne State University | Compositions inhibiting murine MXT ductal carcinoma |
| US5504074A (en) * | 1993-08-06 | 1996-04-02 | Children's Medical Center Corporation | Estrogenic compounds as anti-angiogenic agents |
| HUP0101809A3 (en) * | 1998-03-11 | 2002-07-29 | Endorech Inc Sainte Foy | Inhibitors of type 5 and type 3 17betha-hydroxysteroid dehydrogenase and methods for their use |
-
1999
- 1999-08-06 ID IDW20010531A patent/ID28791A/id unknown
- 1999-08-06 AR ARP990103961A patent/AR021757A1/es unknown
- 1999-08-06 AU AU51449/99A patent/AU5144999A/en not_active Abandoned
- 1999-08-06 WO PCT/CA1999/000724 patent/WO2000007576A2/en not_active Ceased
- 1999-08-06 EP EP99936218A patent/EP1102582A2/de not_active Withdrawn
- 1999-08-06 CA CA002339368A patent/CA2339368A1/en not_active Abandoned
- 1999-08-06 JP JP2000563261A patent/JP2002522380A/ja active Pending
- 1999-08-06 CN CN99811739A patent/CN1322130A/zh active Pending
-
2001
- 2001-02-07 NO NO20010651A patent/NO20010651L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2000007576A3 (en) | 2000-03-30 |
| NO20010651D0 (no) | 2001-02-07 |
| EP1102582A2 (de) | 2001-05-30 |
| WO2000007576A2 (en) | 2000-02-17 |
| AR021757A1 (es) | 2002-08-07 |
| CA2339368A1 (en) | 2000-02-17 |
| CN1322130A (zh) | 2001-11-14 |
| ID28791A (id) | 2001-07-05 |
| AU5144999A (en) | 2000-02-28 |
| JP2002522380A (ja) | 2002-07-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20010651L (no) | Inhibering av type 3 3<alfa>-hydroxysteroiddehydrogenase | |
| NO308037B1 (no) | 16-substituerte-4-aza-androstan 5<alfa>-reduktase-isoenzym 1- inhibitorer og farmasøytisk preparat | |
| RU94046057A (ru) | Ингибиторы активности тестостерон 5 альфа -редуктазы, фармкомпозиция, способ подавления активности, тестостерон 5 альфа -редуктазы | |
| TR199901604T2 (xx) | Tedavide yararl� kinolin ve kinazolin bile�ikleri. | |
| PT668860E (pt) | Piran-2-onas e 5,6-di-hidropiran-2-onas uteis no tratamento do hiv e outros retrovirus | |
| DE69329149D1 (de) | 4-azasteroide als 5-alpha-reduktase | |
| TR200002224T2 (tr) | Matris-bozucu metalloproteinasları inhibe eden sülfonilamino türevleri. | |
| DE69329856D1 (de) | Ester derivate von 4-aza-steroiden | |
| DE69417925D1 (de) | 7-substituierte-4-aza-steroid-derivate als 5-alpha-reductase-hemmer | |
| TR200002784T2 (tr) | Tip 5 ve tip 3 17beta-Hidroksisteroid dehidrojenaz inhibitörleri ve bunların kullanımı için metodlar | |
| MY135732A (en) | 5,6-trimethylenepyrimidin - 4 - one compounds | |
| ATE345125T1 (de) | Biphenylderivate und ihre verwendung als antiandrogene | |
| EA200100571A1 (ru) | Комбинированный способ лечебного воздействия, включающий применение лучевой терапии и ингибитора циклооксигеназы-2(cox-2) для лечения неоплазии | |
| DE69313114D1 (de) | NEUE DELTA-17 UND DELTA-20 UNGESÄTIGTE UND GESATIGTE 17--g(b)-SUBSTITUIERTE-4-AZA-5-g(a)-ANDROSTAN-3-ON VERBINDUNGEN ALS INHIBITOREN VON 5-ALPHA-REDUCTASE | |
| TR199900556T2 (xx) | Prostat hipertrofisini ve prostat kanserini tedavi etmek i�in vas�ta. | |
| ATE183193T1 (de) | 17-amino-substituierte 4-azasteroide als 5-alpha- reductase inhibitoren | |
| MXPA03002495A (es) | Proceso para preparacion de compuestos de n-(fenil sustituido)-3-alquil, aril- y heteroarilsulfonil-2-hidroxi-2-alquil- y haloalquilpropanamida. | |
| ATE198274T1 (de) | 17 beta-aryl-4-aza-steroidderivate | |
| ATE451107T1 (de) | 3-o-sulfamatsteroidderivate als hemmer von estronsulfatase | |
| ES2182487T3 (es) | Procedimiento para el tratamiento de agua en circulacion procedente de una instalacion de laqueado. | |
| NO974801L (no) | Koldrengjöringspreparater basert på alkaner eller cykloalkaner og en organisk forbindelse omfattende en ketongruppe | |
| NO983724D0 (no) | 17-<beta>-syklopropyl (amino/oksi)-4-aza-steroider som aktive inhibitorer av testosteron-5-<alfa>-reduktase og C17-20-lylase | |
| DE69615046D1 (de) | 17-alkyl-7-substituierte-4-aza-steroidderivate | |
| MX9301939A (es) | Composicion farmaceutica que comprende un compuesto inhibidor de 5-ó-reductasa esteroidal. | |
| BR9912318A (pt) | Compostos de 1- (4-arilpiperazin-1-il) -w- [n- (ol, w -dicarboximido) ] alcanos de utilidade como bloqueadores uro-seletivos de 1 - adrenoceptor. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |